Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis.

ABSTRACT:

Background

Progressive fibrosing interstitial lung disease (ILD) is characterised by parenchymal scar formation, leading to high morbidity and mortality. The ability to predict this phenotype remains elusive. We conducted a proteomic analysis to identify novel plasma biomarkers of progressive fibrosing ILD and developed a proteomic signature to predict this phenotype.

Methods

Relative plasma concentrations for 368 biomarkers were determined with use of a semi-quantitative, targeted proteomic platform in patients with connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, or unclassifiable ILD who provided research blood draws at the University of California (discovery cohort) and the University of Texas (validation cohort). Univariable logistic regre

SUBMITTER: Bowman WS 

PROVIDER: S-EPMC9177713 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature